TY - JOUR
T1 - The East–West late lumen loss study
T2 - Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts
AU - Harrison, Robert W.
AU - Radhakrishnan, Vaishnavi
AU - Allen, John C.
AU - Lam, Peter S.
AU - Allocco, Dominic J.
AU - Brar, Sandeep
AU - Fahy, Martin
AU - Zhang, Zhen
AU - Fisher, Rebecca
AU - Ikeno, Fumiaki
AU - Généreux, Philippe
AU - Kimura, Takeshi
AU - Liu, Minglei
AU - Lye, Weng Kit
AU - Nagai, Hirofumi
AU - Suzuki, Yuka
AU - White, Roseann
AU - Krucoff, Mitchell W.
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/12
Y1 - 2018/12
N2 - Background: Regulatory decisions approving new coronary drug-eluting stent (DES) require mechanistic observations of angiographic late lumen loss (LLL). Patient safety and device approval times could be enhanced if angiographic follow-up data were found to be generalizable across jurisdictions and geographies. The objectives were to assess the comparability of in-segment LLL in Eastern and Western DES populations using the world's largest compilation of follow-up quantitative coronary angiography data. Methods: Data from 4 manufacturers involving 29 DES clinical trials in Eastern and Western hemispheres were compiled. “East” and “West” cohorts were defined by trial location. Independent core laboratories quantified in-segment LLL for all studies. East and West were compared before and after adjustment for clinical and anatomic covariates known to correlate with LLL via conditioning on propensity score quintiles. An international panel of experts and regulators prospectively established a clinically meaningful difference between East and West mean in-segment LLL of ±0.40 mm. Results: The data set comprised 2,047 East and 4,456 West patients. Unadjusted mean ± SD for West and East in-segment LLL (mm) was 0.25 ± 0.46 and 0.12 ± 0.42, respectively (difference 0.13 mm; 95% CI 0.11-0.16). Propensity score–adjusted in-segment LLL East and West least squares means were 0.11 and 0.26 mm, respectively (difference 0.15 mm; 95% CI 0.13-0.18). Conclusions: In the world's largest compilation of DES protocol 8- to 13-month angiographic follow-up data, clinically meaningful comparability of in-segment LLL by independent core laboratory quantitative coronary angiography in East and West cohorts was demonstrated in both unadjusted and adjusted comparisons. These findings suggest that DES LLL, once characterized, could be generalized across regulatory jurisdictions over the course of global registration efforts.
AB - Background: Regulatory decisions approving new coronary drug-eluting stent (DES) require mechanistic observations of angiographic late lumen loss (LLL). Patient safety and device approval times could be enhanced if angiographic follow-up data were found to be generalizable across jurisdictions and geographies. The objectives were to assess the comparability of in-segment LLL in Eastern and Western DES populations using the world's largest compilation of follow-up quantitative coronary angiography data. Methods: Data from 4 manufacturers involving 29 DES clinical trials in Eastern and Western hemispheres were compiled. “East” and “West” cohorts were defined by trial location. Independent core laboratories quantified in-segment LLL for all studies. East and West were compared before and after adjustment for clinical and anatomic covariates known to correlate with LLL via conditioning on propensity score quintiles. An international panel of experts and regulators prospectively established a clinically meaningful difference between East and West mean in-segment LLL of ±0.40 mm. Results: The data set comprised 2,047 East and 4,456 West patients. Unadjusted mean ± SD for West and East in-segment LLL (mm) was 0.25 ± 0.46 and 0.12 ± 0.42, respectively (difference 0.13 mm; 95% CI 0.11-0.16). Propensity score–adjusted in-segment LLL East and West least squares means were 0.11 and 0.26 mm, respectively (difference 0.15 mm; 95% CI 0.13-0.18). Conclusions: In the world's largest compilation of DES protocol 8- to 13-month angiographic follow-up data, clinically meaningful comparability of in-segment LLL by independent core laboratory quantitative coronary angiography in East and West cohorts was demonstrated in both unadjusted and adjusted comparisons. These findings suggest that DES LLL, once characterized, could be generalized across regulatory jurisdictions over the course of global registration efforts.
UR - http://www.scopus.com/inward/record.url?scp=85055249705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055249705&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2018.08.017
DO - 10.1016/j.ahj.2018.08.017
M3 - Article
C2 - 30342296
AN - SCOPUS:85055249705
SN - 0002-8703
VL - 206
SP - 61
EP - 71
JO - American Heart Journal
JF - American Heart Journal
ER -